{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:33:49Z","timestamp":1794540829616,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim was to describe the population of patients with moderate rheumatoid arthritis (RA) in the United Kingdom and the burden of disease from the perspectives of the patient, caregiver, and health service.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this descriptive study, retrospective patient-level data were extracted from hospital medical records to assess healthcare resource utilisation and validated outcome measures were administered via questionnaire to patients with moderate RA (Disease Activity Score [DAS28] between 3.2 and 5.1) from eight secondary care centres, and their caregivers. Patient-reported outcome instruments were scored according to licensed manuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Outcome measures were completed by 102 patients and 38 caregivers. The mean EuroQoL-5 dimension-5 level crosswalk index value for patients was 0.62 (SD 0.24) compared to an England population norm of 0.82. Mean pain VAS score was 37.7 (SD 24.0) and mean Health Assessment Questionnaire Disability Index was 1.1 (SD 0.8). In employed patients who completed the Work Productivity and Activity Impairment questionnaire (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200926), a mean 29% (SD 26%) reduction in work productivity was recorded. Patients experienced significant fatigue as a result of their RA (median Functional Assessment of Chronic Illness Therapy fatigue score 17.2 of a possible 52, interquartile range [IQR] 11.0\u201328.8). Over 50% of caregivers reported providing &gt;\u20097\u2009h of support care per week to the patient with RA, and 16 and 11% took paid\/unpaid leave or reduced working hours, respectively. Mean Caregiver Reaction Assessment subscale scores were 1.9 (SD 0.9) for finance, 1.7 (SD 0.8) for health, 2.3 (SD 1.0) for schedule disruption, and 1.9 (SD 0.8) for family support. Patients had a mean 5.5 (SD 4.1) outpatient attendances and a median 9.0 (IQR 2.0\u201320.0) diagnostic and monitoring tests in the 12\u2009months prior to enrolment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study shows that moderate RA has a considerable impact on healthcare resources and on patients\u2019 and caregivers\u2019 lives. There is scope to improve the management of patients with moderate RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-021-04110-1","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T10:02:46Z","timestamp":1615629766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Direct healthcare resource utilisation, health-related quality of life, and work productivity in patients with moderate rheumatoid arthritis: an observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"James","family":"Galloway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Lyn","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Wallington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4556-2288","authenticated-orcid":false,"given":"Sophee","family":"Blanthorn-Hazell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,13]]},"reference":[{"key":"4110_CR1","unstructured":"Arthritis Research UK. State of musculoskeletal health 2017: Arthritis and other musculoskeletal conditions in numbers. Available from: http:\/\/www.arthritisresearchuk.org\/arthritis-information\/data-and-statistics\/state-of-musculoskeletal-health.aspx. [cited 2018 Jan 8]"},{"key":"4110_CR2","unstructured":"National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management (CG79) . 2009. Available from: https:\/\/www.nice.org.uk\/guidance\/cg79 [cited 2018 Jan 8]"},{"issue":"5","key":"4110_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/rheumatology\/37.5.546","volume":"37","author":"DL Scott","year":"1998","unstructured":"Scott DL, Shipley M, Dawson A, Edwards S, Symmons DP, Woolf AD. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol. 1998;37(5):546\u201354.","journal-title":"Br J Rheumatol"},{"key":"4110_CR4","unstructured":"Rheumatoid arthritis - NICE CKS. Available from: https:\/\/cks.nice.org.uk\/rheumatoid-arthritis#!backgroundsub:1. [cited 2018 Jan 17]"},{"issue":"2","key":"4110_CR5","doi-asserted-by":"publisher","first-page":"rkaa041","DOI":"10.1093\/rap\/rkaa041","volume":"4","author":"J Galloway","year":"2020","unstructured":"Galloway J, Capron J-P, De Leonardis F, Fakhouri W, Rose A, Kouris I, et al. The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. Rheumatol Adv Pract. 2020;4(2):rkaa041.","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"4110_CR6","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.4103\/jfmpc.jfmpc_53_20","volume":"9","author":"M Mandal","year":"2020","unstructured":"Mandal M, Dasgupta A, Dutt D, Taraphdar P, Ghosh P, Paul B. Quantification of health-related quality of life among patients with rheumatoid arthritis: an institution-based study in Kolkata, West Bengal. J Fam Med Prim Care. 2020;9(8):3970\u20136.","journal-title":"J Fam Med Prim Care"},{"issue":"2","key":"4110_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/acr.20345","volume":"63","author":"M Margaretten","year":"2011","unstructured":"Margaretten M, Barton J, Julian L, Katz P, Trupin L, Tonner C, et al. Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res. 2011;63(2):240\u20136.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"4110_CR8","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/rheumatology\/keq043","volume":"49","author":"D van Hoogmoed","year":"2010","unstructured":"van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatol Oxf Engl. 2010;49(7):1294\u2013302.","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"4110_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.20539","volume":"51","author":"I Rupp","year":"2004","unstructured":"Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GAM. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum. 2004;51(4):578\u201385.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4110_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/01.mlr.0000204257.25875.04","volume":"44","author":"X Li","year":"2006","unstructured":"Li X, Gignac MAM, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care. 2006 Apr;44(4):304\u201310.","journal-title":"Med Care"},{"issue":"10","key":"4110_CR11","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1093\/rheumatology\/keaa027","volume":"59","author":"JM Gwinnutt","year":"2020","unstructured":"Gwinnutt JM, Leggett S, Lunt M, Barton A, Hyrich KL, Walker-Bone K, et al. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatol Oxf Engl. 2020;59(10):2908\u201319.","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"4110_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/occmed\/kqi171","volume":"56","author":"W Burton","year":"2006","unstructured":"Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med Oxf Engl. 2006;56(1):18\u201327.","journal-title":"Occup Med Oxf Engl"},{"issue":"3","key":"4110_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/rheumatology\/ket373","volume":"53","author":"DF McWilliams","year":"2014","unstructured":"McWilliams DF, Varughese S, Young A, Kiely PD, Walsh DA. Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort. Rheumatol Oxf Engl. 2014;53(3):473\u201381.","journal-title":"Rheumatol Oxf Engl"},{"issue":"3","key":"4110_CR14","first-page":"334","volume":"31","author":"G da Rocha Castelar Pinheiro","year":"2013","unstructured":"da Rocha Castelar Pinheiro G, Khandker RK, Sato R, Rose A, Piercy J. Impact of rheumatoid arthritis on quality of life, work productivity and resource utilisation: an observational, cross-sectional study in Brazil. Clin Exp Rheumatol. 2013;31(3):334\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"4110_CR15","unstructured":"National Rheumatoid Arthritis Society and University of Chester. The Burden of Rheumatoid Arthritis across Europe: a Socioeconomic Survey (BRASS) - Summary Report. Available from: https:\/\/www.nras.org.uk\/data\/files\/Publications\/Surveys%20Reports\/UoC_HCD_BRASS%20Summary%20Report%20FINAL.pdf. [cited 2018 Feb 6]"},{"key":"4110_CR16","unstructured":"Rheumatoid arthritis in adults: management | Guidance and guidelines | NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/ng100. [cited 2019 Feb 18]."},{"issue":"1","key":"4110_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4110_CR18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","volume":"77","author":"SA Bergstra","year":"2018","unstructured":"Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis. 2018;77(10):1413\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4110_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/rheumatology\/kex042","volume":"56","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, et al. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. Rheumatol Oxf Engl. 2017;56(7):1095\u2013101.","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"4110_CR20","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/rheumatology\/keq444","volume":"50","author":"E Hallert","year":"2011","unstructured":"Hallert E, Husberg M, Skogh T. 28-joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project. Rheumatol Oxf Engl. 2011;50(7):1259\u201367.","journal-title":"Rheumatol Oxf Engl"},{"issue":"3","key":"4110_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3899\/jrheum.100589","volume":"38","author":"A Beresniak","year":"2011","unstructured":"Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol. 2011;38(3):439\u201345.","journal-title":"J Rheumatol"},{"issue":"10","key":"4110_CR22","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/annrheumdis-2012-201918","volume":"72","author":"C Barnabe","year":"2013","unstructured":"Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr SG, Martin L, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. 2013;72(10):1664\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4110_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12955-017-0813-7","volume":"15","author":"ED Bacci","year":"2017","unstructured":"Bacci ED, DeLozier AM, Lin C-Y, Gaich CL, Rooney T, Hoffman R, et al. Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis. Health Qual Life Outcomes. 2017;15(1):239.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"4110_CR24","doi-asserted-by":"publisher","first-page":"R177","DOI":"10.1186\/ar3141","volume":"12","author":"W Zhang","year":"2010","unstructured":"Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177.","journal-title":"Arthritis Res Ther"},{"key":"4110_CR25","unstructured":"Husni M, Kosinski M, Rendas-Baum R, Kafka S, Han C, Chan E, et al. Psychometric Properities of the patient related outcome measure FACIT-fatigue in rheumatic arthritis and psoriatic arthritis: a literature review. Arthritis Rheumatol. 2019;71(suppl 10). Available from: https:\/\/acrabstracts.org\/abstract\/psychometric-properities-of-the-patient-related-outcome-measure-facit-fatigue-in-rheumatic-arthritis-and-psoriatic-arthritis-a-literature-review\/."},{"issue":"2","key":"4110_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137\u201345.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"4110_CR27","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s10067-018-4285-x","volume":"37","author":"L Renskers","year":"2018","unstructured":"Renskers L, van Uden RJJC, Huis AMP, Rongen SAA, Teerenstra S, van Riel PLCM. Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis. Clin Rheumatol. 2018;37(12):3191\u20139.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"4110_CR28","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehab"},{"issue":"8","key":"4110_CR29","first-page":"1528","volume":"35","author":"L Linde","year":"2008","unstructured":"Linde L, S\u00f8rensen J, Ostergaard M, H\u00f8rslev-Petersen K, Hetland ML. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol. 2008;35(8):1528\u201337.","journal-title":"J Rheumatol"},{"issue":"Suppl 11","key":"4110_CR30","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"GA Hawker","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). Arthritis Care Res. 2011;63(Suppl 11):S240\u201352.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"4110_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai J-S, Chang C-H, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528\u201338.","journal-title":"Cancer."},{"issue":"5","key":"4110_CR32","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811\u20139.","journal-title":"J Rheumatol"},{"key":"4110_CR33","unstructured":"WPAI scoring, Reilly Associates. Available from: http:\/\/www.reillyassociates.net\/WPAI_Scoring.html. [cited 2019 Apr 17]"},{"issue":"4","key":"4110_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/nur.4770150406","volume":"15","author":"CW Given","year":"1992","unstructured":"Given CW, Given B, Stommel M, Collins C, King S, Franklin S. The caregiver reaction assessment (CRA) for caregivers to persons with chronic physical and mental impairments. Res Nurs Health. 1992;15(4):271\u201383.","journal-title":"Res Nurs Health"},{"key":"4110_CR35","unstructured":"Reference costs | NHS Improvement. Available from: https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. [cited 2019 Mar 22]"},{"key":"4110_CR36","unstructured":"BNF: British National Formulary - NICE. Available from: https:\/\/bnf.nice.org.uk\/. [cited 2019 Apr 17]"},{"issue":"10","key":"4110_CR37","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","volume":"77","author":"L Kearsley-Fleet","year":"2018","unstructured":"Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77(10):1405\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4110_CR38","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/rheumatology\/key224","volume":"57","author":"MJ Cook","year":"2018","unstructured":"Cook MJ, Bellou E, Bowes J, Sergeant JC, O\u2019Neill TW, Barton A, et al. The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK biobank. Rheumatol Oxf Engl. 2018;57(12):2172\u201382.","journal-title":"Rheumatol Oxf Engl"},{"issue":"8","key":"4110_CR39","doi-asserted-by":"publisher","first-page":"e007696","DOI":"10.1136\/bmjopen-2015-007696","volume":"5","author":"RA Watts","year":"2015","unstructured":"Watts RA, Mooney J, Barton G, MacGregor AJ, Shepstone L, Irvine L, et al. The outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis: a non-randomised pragmatic study. BMJ Open. 2015;5(8):e007696.","journal-title":"BMJ Open"},{"issue":"9","key":"4110_CR40","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s10067-013-2240-4","volume":"32","author":"K Pavelka","year":"2013","unstructured":"Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in central and Eastern Europe in the PRESERVE study. Clin Rheumatol. 2013;32(9):1275\u201381.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4110_CR41","doi-asserted-by":"publisher","first-page":"e0169946","DOI":"10.1371\/journal.pone.0169946","volume":"12","author":"T Jorgensen","year":"2017","unstructured":"Jorgensen T, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: a prospective observational study of patients registered in the south Swedish SSATG registry. PLoS One. 2017;12(2):e0169946.","journal-title":"PLoS One"},{"issue":"1","key":"4110_CR42","doi-asserted-by":"publisher","first-page":"e000615","DOI":"10.1136\/rmdopen-2017-000615","volume":"4","author":"PC Taylor","year":"2018","unstructured":"Taylor PC, Alten R, Gomez-Reino JJ, Caporali R, Bertin P, Sullivan E, et al. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. RMD Open. 2018;4(1):e000615.","journal-title":"RMD Open"},{"issue":"4","key":"4110_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.24869\/psyd.2018.452","volume":"30","author":"I \u017dagar","year":"2018","unstructured":"\u017dagar I, Delimar V, Pap M, Peri\u0107 D, Lakta\u0161i\u0107 \u017derjavi\u0107 N, Peri\u0107 P. Prevalence and correlation of depressive symptoms with functional scores, therapy and disease activity among Croatian patients with rheumatoid arthritis: a preliminary study. Psychiatr Danub. 2018;30(4):452\u20138.","journal-title":"Psychiatr Danub"},{"issue":"1","key":"4110_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13075-016-1004-3","volume":"18","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016;18(1):114.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"4110_CR45","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3899\/jrheum.161214","volume":"44","author":"S Twigg","year":"2017","unstructured":"Twigg S, Hensor EMA, Emery P, Tennant A, Morgan AW. Yorkshire early arthritis register consortium. Patient-reported outcomes as predictors of change in disease activity and disability in early rheumatoid arthritis: results from the Yorkshire early arthritis register. J Rheumatol. 2017;44(9):1331\u201340.","journal-title":"J Rheumatol"},{"key":"4110_CR46","doi-asserted-by":"publisher","unstructured":"Al-Herz A, Saleh K, Al-Awadhi A, Al-Kandari W, Hasan E, Ghanem A, et al. Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait. Clin Rheumatol. 2020. https:\/\/doi.org\/10.1007\/s10067-020-05444-2.","DOI":"10.1007\/s10067-020-05444-2"},{"issue":"10","key":"4110_CR47","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/acr.22022","volume":"65","author":"D Hone","year":"2013","unstructured":"Hone D, Cheng A, Watson C, Huang B, Bitman B, Huang X. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2013;65(10):1564\u201372.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4110_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s42358-019-0090-8","volume":"59","author":"RM Xavier","year":"2019","unstructured":"Xavier RM, Zerbini CAF, Pollak DF, Morales-Torres JLA, Chalem P, Restrepo JFM, et al. Burden of rheumatoid arthritis on patients\u2019 work productivity and quality of life. Adv Rheumatol Lond Engl. 2019;59(1):47.","journal-title":"Adv Rheumatol Lond Engl"},{"issue":"12","key":"4110_CR49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40273-016-0441-9","volume":"34","author":"PSJ Miller","year":"2016","unstructured":"Miller PSJ, Hill H, Andersson FL. Nocturia work productivity and activity impairment compared with other common chronic diseases. PharmacoEconomics. 2016;34(12):1277\u201397.","journal-title":"PharmacoEconomics."},{"key":"4110_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12891-015-0562-x","volume":"16","author":"M van Vilsteren","year":"2015","unstructured":"van Vilsteren M, Boot C, Knol D, van Schaardenburg D, Voskuyl A, Steenbeek R. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015;16:107.","journal-title":"BMC Musculoskelet Disord"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-021-04110-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:04:46Z","timestamp":1698015886000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,13]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4110"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04110-1","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,13]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A favourable opinion was obtained from the North West Liverpool Central Research Ethics Committee (reference 18\/NW\/0286) following proportionate review, and approval from the Research and Development department of each NHS Trust or Health Board was obtained prior to study start. Written informed consent was obtained for questionnaire completion and access to and extraction of data from hospital records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JG has received honoraria and speaker fees from Abbvie, BMS, Celgene, Janssen, Lilly, Pfizer, and UCB. BP has received honoraria for advisory boards and speaking from AbbVie, Pfizer, UCB, Astra-Zeneca, GSK, Novartis, BMS, and Celltrion. ALT has received honoraria for advisory boards and speaking from Abbvie, Lilly, Janssen, Novartis, and Pfizer. JM has served on advisory boards for Abbvie, Pfizer, BMS, and Lilly and has received speaking honoraria from Pfizer, BMS, Novartis, and Lilly. ZC has received honoraria for advisory boards and speaking from AbbVie, Pfizer, UCB, Lilly, and Roche. SBH and CB are employees at AbbVie Limited. MW is an employee of OPEN VIE. JE and SB have no disclosures or conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}